GSK’s flop Potiga is picked up and headed for a quick makeover for pediatric epilepsy. Any bets on the prospective price?
GlaxoSmithKline took a considerable amount of heat last year when the pharma giant decided to yank a drug called Potiga, which had been approved as an anti-convulsant for adults but often sold off label to treat an extremely rare form of epilepsy caused by an errant KCNQ2 gene. The drug was considered a lifesaver by the small group of kids and their families that benefited from it, but GSK didn’t see enough of a commercial return to make it worthwhile. So they discarded it, along with other parts of the company that have been stripped away in pursuit of making the company more profitable in the long run.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
